New CAR-T therapy targets hard-to-treat blood cancers after other options fail

This early-phase study tests a new type of CAR-T cell therapy called Sup19 in 9 adults with B-cell blood cancers (like leukemia or lymphoma) that either stopped responding to previous CD19-targeted treatments or have low levels of the CD19 protein. The main goal is to check safety, especially serious side effects like cytokine release syndrome, and to see if the therapy can shrink tumors or lead to remission. This is a small, first-in-human trial, so it focuses on safety and early signs of effectiveness.